| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
1 Division of Radiation and Cancer Biology, Department of Radiation Oncology, and 2 Department of Health Policy and Research, Stanford University School of Medicine, Stanford, California
Cisplatin is a crucial agent in the treatment of many solid tumors, yet many tumors have either acquired or intrinsic resistance to the drug. We have used the homozygous diploid deletion pool of Saccharomyces cerevisiae, containing 4728 strains with individual deletion of all nonessential genes, to systematically identify genes that when deleted confer sensitivity to the anticancer agents cisplatin, oxaliplatin, and mitomycin C. We found that deletions of genes involved in nucleotide excision repair, recombinational repair, postreplication repair including translesional synthesis, and DNA interstrand cross-link repair resulted in sensitivity to all three of the agents, although with some differences between the platinum drugs and mitomycin C in the spectrum of required translesional polymerases. Putative defective repair of oxidative damage (imp2'
strain) also resulted in sensitivity to platinum and oxaliplatin, but not to mitomycin C. Surprisingly in light of their different profiles of clinical activity, cisplatin and oxaliplatin have very similar sensitivity profiles. Finally, we identified three novel genes (PSY1–3, "platinum sensitivity") that, when deleted, demonstrate sensitivity to cisplatin and oxaliplatin, but not to mitomycin C. Our results emphasize the importance of multiple DNA repair pathways responsible for normal cellular resistance to all three of the agents. Also, the similarity of the sensitivity profiles of the platinum agents with that of the known DNA interstrand cross-linking agent mitomycin C, and the importance of the gene PSO2 known to be involved in DNA interstrand cross-link repair strongly suggests that interstrand cross-links are important toxic lesions for cisplatin and oxaliplatin, at least in yeast.
This article has been cited by other articles:
|
|
 |
|
  M. Rojas, C. W. Wright, B. Pina, and J. Portugal Genomewide Expression Profiling of Cryptolepine-Induced Toxicity in Saccharomyces cerevisiae Antimicrob. Agents Chemother., November 1, 2008; 52(11): 3844 - 3850. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. G. Minko, M. B. Harbut, I. D. Kozekov, A. Kozekova, P. M. Jakobs, S. B. Olson, R. E. Moses, T. M. Harris, C. J. Rizzo, and R. S. Lloyd Role for DNA Polymerase {kappa} in the Processing of N2-N2-Guanine Interstrand Cross-links J. Biol. Chem., June 20, 2008; 283(25): 17075 - 17082. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Tan, H. Feizi, C. Luo, S. H. Fan, T. Ravasi, and T. G. Ideker A systems approach to delineate functions of paralogous transcription factors: Role of the Yap family in the DNA damage response PNAS, February 26, 2008; 105(8): 2934 - 2939. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Malina, O. Novakova, M. Vojtiskova, G. Natile, and V. Brabec Conformation of DNA GG Intrastrand Cross-Link of Antitumor Oxaliplatin and Its Enantiomeric Analog Biophys. J., December 1, 2007; 93(11): 3950 - 3962. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-H. Kim, A. H. Holway, S. Wolff, A. Dillin, and W. M. Michael SMK-1/PPH-4.1 mediated silencing of the CHK-1 response to DNA damage in early C. elegans embryos J. Cell Biol., October 8, 2007; 179(1): 41 - 52. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Nomura, N. Adachi, and H. Koyama Human Mus81 and FANCB independently contribute to repair of DNA damage during replication Genes Cells, October 1, 2007; 12(10): 1111 - 1122. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Van Driessche, H. Alexander, J. Min, A. Kuspa, S. Alexander, and G. Shaulsky Global transcriptional responses to cisplatin in Dictyostelium discoideum identify potential drug targets PNAS, September 25, 2007; 104(39): 15406 - 15411. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Mendoza, E. O. Booth, G. Shaulsky, and R. A. Firtel MEK1 and Protein Phosphatase 4 Coordinate Dictyostelium Development and Chemotaxis Mol. Cell. Biol., May 15, 2007; 27(10): 3817 - 3827. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Zakrzewska, A. Boorsma, D. Delneri, S. Brul, S. G. Oliver, and F. M. Klis Cellular Processes and Pathways That Protect Saccharomyces cerevisiae Cells against the Plasma Membrane-Perturbing Compound Chitosan Eukaryot. Cell, April 1, 2007; 6(4): 600 - 608. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Liao, B. Hu, M. J. Arno, and B. Panaretou Genomic Screening in Vivo Reveals the Role Played by Vacuolar H+ ATPase and Cytosolic Acidification in Sensitivity to DNA-Damaging Agents Such as Cisplatin Mol. Pharmacol., February 1, 2007; 71(2): 416 - 425. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Bartz, Z. Zhang, J. Burchard, M. Imakura, M. Martin, A. Palmieri, R. Needham, J. Guo, M. Gordon, N. Chung, et al. Small Interfering RNA Screens Reveal Enhanced Cisplatin Cytotoxicity in Tumor Cells Having both BRCA Network and TP53 Disruptions Mol. Cell. Biol., December 15, 2006; 26(24): 9377 - 9386. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.-C. Gingras, M. Caballero, M. Zarske, A. Sanchez, T. R. Hazbun, S. Fields, N. Sonenberg, E. Hafen, B. Raught, and R. Aebersold A Novel, Evolutionarily Conserved Protein Phosphatase Complex Involved in Cisplatin Sensitivity Mol. Cell. Proteomics, November 1, 2005; 4(11): 1725 - 1740. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hellauer, G. Lesage, A.-M. Sdicu, and B. Turcotte Large-Scale Analysis of Genes that Alter Sensitivity to the Anticancer Drug Tirapazamine in Saccharomyces cerevisiae Mol. Pharmacol., November 1, 2005; 68(5): 1365 - 1375. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R.-Y. Huang, M. Eddy, M. Vujcic, and D. Kowalski Genome-Wide Screen Identifies Genes Whose Inactivation Confer Resistance to Cisplatin in Saccharomyces cerevisiae Cancer Res., July 1, 2005; 65(13): 5890 - 5897. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. S. El-Deiry Meeting Report: The International Conference on Tumor Progression and Therapeutic Resistance Cancer Res., June 1, 2005; 65(11): 4475 - 4484. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Deng, J. A. Brown, D. You, and J. M. Brown Multiple Endonucleases Function to Repair Covalent Topoisomerase I Complexes in Saccharomyces cerevisiae Genetics, June 1, 2005; 170(2): 591 - 600. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Shor, J. Weinstein, and R. Rothstein A Genetic Screen for top3 Suppressors in Saccharomyces cerevisiae Identifies SHU1, SHU2, PSY3 and CSM2: Four Genes Involved in Error-Free DNA Repair Genetics, March 1, 2005; 169(3): 1275 - 1289. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
